This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study were presented at the 2026 Annual Meeting of The Menopause Society in San Diego Oct. 20–24, 2026.

Hormone therapy has proven to be successful in managing a wide array of bothersome menopause symptoms, especially hot flashes. A challenge, however, is that fluctuations in estrogen levels may influence migraines.

Researchers in a new study sought to evaluate the associations of hormone therapy with migraine outcomes, including incidence, severity, frequency, duration and analgesic use in postmenopausal women, independently of the route of administration. They based their findings on five studies that collectively included nearly 24,000 women. The pooled analysis showed a mean migraine incidence of 18.94%.

Based on their findings, the researchers concluded that hormone therapy was associated with increased frequency of migraine attacks and longer duration of migraine episodes. However, no significant differences were observed in the number of analgesics used per month or in migraine severity scores.

Further clinical trials are necessary to better understand the physiopathology and to guide more efficient treatments.

"Migraines can have a significant impact on quality of life, particularly during the menopause transition when many women experience changes in their symptoms.

Source link